ND-L02-s0201-005 Phase 2 randomized double blind placebo controlled study to evaluate safety, tolerability, biological activity, and PK of ND-L02-s0201 in subjects with IPF

Administered By

Awarded By

Contributors

Start/End

  • August 24, 2018 - August 23, 2020